Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype (GBM) is the most malignant type of primary brain tumor and in spite of extensive chemo-radiotherapy treatment schemes and surgical resection, the median survival remains limited to approximately 8 months.1 Understanding the molecular profile of GBM might guide treatment options by revealing putative targets and so improve patient survival. Here, IDH3A is linked to glioblastoma.